ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   
 Top Breaking News
 Thursday, July 31, 2014

AstraZeneca PLC (AZN) Steps Up Push Into Cancer Immunotherapy, Falls Behind Rivals Such As Bristol-Myers Squibb Company (BMY), Merck & Co., Inc. (MRK), And Roche (RHHBY)

FDA Panel Reviews Safety Of Baxter International, Inc. (BAX)'s Experimental Drug For Immune System Disorders

CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV

Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Alirocumab Cuts Cholesterol In Nine Late-Stage Trials

Second Failure Of The Month As Targacept, Inc. (TRGT) Halts Development Of Bladder Drug, Shares Plunge

FDA Rejects Redwood City's AcelRx Pharmaceuticals (ACRX) Painkiller Dispensing Device; Stock Plunges -34.35% At 9:37AM ET

Quark Pharmaceuticals Inc. Reports Favorable Data From Phase 2 Clinical Trial Evaluating Investigational siRNA QPI-1002

AstraZeneca PLC (AZN) Fights With Pediatrician Group Over Preemie Drug Guidelines

More News



 Yesterday's Most Popular News 
Second Failure Of The Month As Targacept, Inc. (TRGT) Halts Development Of Bladder Drug, Shares Plunge

Want To Live Longer? Go For A Five Minute Run, Says Iowa State University Researcher

Why Men Like Nice Women And Why Women Like Bad Boys, University of Rochester Study

FDA Rejects Redwood City's AcelRx Pharmaceuticals (ACRX) Painkiller Dispensing Device; Stock Plunges -34.35% At 9:37AM ET

An FDA-Approved Multiple Sclerosis Drug Can Alter Memory? University of California, Irvine Study

Quark Pharmaceuticals Inc. Reports Favorable Data From Phase 2 Clinical Trial Evaluating Investigational siRNA QPI-1002

Slow Walking Speed And Memory Issues Linked To Early Signs Of Dementia, Albert Einstein College of Medicine Study

Pessimism Is From Your Brain, University College London Study

AstraZeneca PLC (AZN) Fights With Pediatrician Group Over Preemie Drug Guidelines

FDA Approves Purdue Pharma L.P.’s Hard-to-Abuse Narcotic Painkiller


 
-

 Featured Stories
 

  Today's Top Jobs

 Featured Employer
About Genzyme Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis. Learn more at www.jobsatgenzyme.com. Follow our jobs on Twitter www.twitter.com/genzymejobs. Follow us on LinkedIn http://www.linkedin.com/company/genzyme. About Sanofi Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Show me jobs for this employer

 Careers
 
More Career Tips